MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named ...
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for ...
MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University ...
MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has joined the 1000 Genomes ...
PacBio's Advanced Sequencing Solutions Enable Breakthrough in Understanding Rare Mendelian Condition
PacBio announced its involvement in a groundbreaking study published in Nature Genetics, which utilized its advanced sequencing technology to explore the genetic basis of a rare Mendelian condition in ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, announced innovations to its Revio and Vega platforms last week. The innovations are expected to lower sequencing costs, add ...
In a paper published on aBIOTECH, the authors introduce BacPhase, a sequence-based phasing method that uses restriction ...
MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ...
Pacific Biosciences of California, Inc. PACB and Intus Bio, a leader in microbiome research and discovery, recently unveiled GutID, the first commercial human gut health test powered by Intus Bio’s ...
PacBio announced the early shipment of its Vega benchtop sequencing system and the launch of SPRQ chemistry, enabling affordable HiFi genome sequencing for under $500 on the Revio system. Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results